每经AI快讯，8月21日，中证转债指数午盘上涨0.75%，报485.73点。其中，东时转债、水羊转债、大元 转债、赛龙转债、易瑞转债涨幅居前，分别涨20.00%、11.18%、9.89%、8.02%、7.47%。崇达转2、金 田转债、金轮转债、力诺转债、博瑞转债跌幅居前，分别跌6.55%、5.42%、4.50%、3.74%、3.38%。 （文章来源：每日经济新闻） ...

Group 1 - The China Securities Convertible Bond Index rose by 0.23%, closing at 453.86 points [1] - Hongfeng Convertible Bond increased by 20%, Borui Convertible Bond rose by 11.60%, and Huahong Convertible Bond gained 7.14% [1] - Bohui Convertible Bond decreased by 5.20%, Jinxian Convertible Bond fell by 5.05%, and Haomei Convertible Bond dropped by 2.53% [1]

Group 1 - The company, BrightGene Bio-Medical Technology Co., Ltd., issued convertible bonds totaling RMB 465 million, with a net fundraising amount of RMB 456.83 million after deducting issuance costs [3][18]. - The bonds have a maturity period of six years, from January 4, 2022, to January 3, 2028, with a face value of RMB 100 per bond [3][4]. - The coupon rates for the bonds are structured to increase over the years, starting at 0.4% in the first year and reaching 3% in the sixth year [3][4]. Group 2 - The company reported a revenue of RMB 1.28 billion for the fiscal year 2024, representing an 8.74% increase from the previous year [17]. - The net profit attributable to shareholders decreased by 3.12% to RMB 180.51 million, primarily due to increased R&D expenses [17]. - The company’s total assets increased by 2.63% to RMB 5.16 billion, indicating stable growth in its financial position [17]. Group 3 - The company focuses on innovative pharmaceutical development, emphasizing original drugs and complex formulations to meet unmet clinical needs globally [15][16]. - Key therapeutic areas include antiviral, antifungal, immunosuppressive, respiratory, oncology, and metabolic diseases, with core products in each category [16]. - The company has a strong commitment to R&D, with R&D expenses increasing by 19.65% year-on-year, reflecting its strategy of being research-driven [17]. Group 4 - The bonds are rated AA- by Dongfang Jincheng International Credit Rating Co., Ltd., with a stable outlook, indicating a strong credit profile [5][21]. - The company has established a dedicated fund management system to ensure the proper use of raised funds, adhering to regulatory requirements [20]. - The company has not experienced any defaults on bond repayments, demonstrating a stable repayment capability [21].

Group 1 - The company has announced a cash dividend distribution plan for the year 2024, approving a distribution of 0.96 yuan per 10 shares to all shareholders [2] - The dividend distribution will not include capital reserve transfers or bonus shares, and any changes in the total share capital before the distribution date will lead to adjustments in the total distribution amount [2] - The company will adjust the conversion price of "Bright Convertible Bonds" in accordance with the relevant regulations after the implementation of the dividend distribution plan [2] Group 2 - The trading of "Bright Convertible Bonds" will be suspended from June 12, 2025, until the equity distribution registration date, with resumption of trading on the first trading day after the registration date [3] - The company will disclose the implementation announcement of the equity distribution, the adjustment of the conversion price for "Bright Convertible Bonds," and the total cash dividend amount on June 13, 2025 [3] - Holders of convertible bonds wishing to enjoy the dividend distribution must convert their bonds before June 11, 2025 [3]

Group 1 - The China Securities Convertible Bond Index opened up by 0.04% [1] - BoRui Convertible Bond, Zhengyu Convertible Bond, and Yitian Convertible Bond rose by over 1% [1] - Hongqiang Convertible Bond fell by nearly 1% [1]

Core Viewpoint - The announcement provides an update on the conversion status of the "博瑞转债" (Bright Gene Convertible Bonds) and outlines the current state of the company's convertible bonds, including the amount converted and remaining unconverted bonds. Group 1: Convertible Bond Issuance Overview - The company issued 4.65 million convertible bonds with a total value of RMB 46.5 million on January 4, 2022, with a maturity period of six years starting from the issuance date [2]. - The bonds began trading on the Shanghai Stock Exchange on January 27, 2022, under the name "博瑞转债" and code "118004" [2]. Group 2: Conversion Status - As of March 31, 2025, RMB 100,000 worth of bonds had been converted into 2,870 shares, representing 0.0007% of the total shares before conversion [1][5]. - By the same date, a total of RMB 159,000 had been converted into 4,550 shares, which is 0.0011% of the total shares before conversion [1][5]. - The remaining unconverted amount of the convertible bonds is RMB 464,835,000, accounting for 99.9645% of the total issuance [1][5]. Group 3: Share Capital Changes - The total share capital before the conversion was 422,466,646 shares, which increased to 422,469,516 shares after the conversion of the bonds [5].

Core Viewpoint - The company maintains its credit rating of "AA-" with a stable outlook for both its corporate entity and the "Bory Pharmaceutical Convertible Bonds" [1][2] Group 1: Credit Rating Information - The previous credit rating for the company was "AA-" with a stable outlook, and the same rating applies to the "Bory Convertible Bonds" [1] - The recent credit rating report from Dongfang Jincheng International Credit Assessment Co., Ltd. confirms the maintenance of the company's credit rating at "AA-" and the stable outlook [2] - The credit rating report is available on the Shanghai Stock Exchange website, detailing the company's and bonds' ratings for the year 2025 [2]

Group 1 - The Zhongzheng Convertible Bond Index opened lower by 0.04% [1] - Bojun Convertible Bond increased by nearly 4% [1] - Borui Convertible Bond rose over 3% [1] Group 2 - Outong Convertible Bond and Jiemei Convertible Bond both increased by over 2% [1] - Hongqiang Convertible Bond and Jing23 Convertible Bond fell nearly 2% [1]

Core Viewpoint - The company has decided not to exercise the early redemption rights of its convertible bonds, despite triggering the conditional redemption clause due to stock price performance [1][6]. Group 1: Conditional Redemption Trigger - From April 28, 2025, to May 21, 2025, the company's stock price met the condition of closing at or above 130% of the conversion price for 15 out of 30 trading days, triggering the conditional redemption clause [1][5]. - The conversion price for the bonds is set at 45.29 CNY per share [5]. Group 2: Decision on Early Redemption - On May 21, 2025, the company's board of directors held a meeting and approved the decision not to redeem the "BoRui Convertible Bonds" early, considering various factors including operational performance and market conditions [6]. - The company will reassess the situation after August 22, 2025, to determine if the redemption clause is triggered again [2][6]. Group 3: Convertible Bond Issuance Overview - The company issued 4.65 million convertible bonds with a total value of 465 million CNY, with a maturity period of six years starting from January 4, 2022 [2]. - The bonds were listed on the Shanghai Stock Exchange on January 27, 2022, under the name "BoRui Convertible Bonds" [2]. Group 4: Conversion Price Adjustments - The conversion price has been adjusted multiple times due to annual profit distributions, with the latest adjustment occurring on June 2023 [3][4].